Drug intelligence / Profile preview

DM-007

Development stage: Preclinical
Lead developer: Doma Pharmaceutical Technology
Modality: Small Molecules

Overview

DM-007 is an investigational drug candidate developed by Doma Biopharmaceutical Suzhou. It is being studied for the treatment of neoplasms, specifically solid tumors. As of March 2025, its highest global R&D status is preclinical, and there are no publicly available details regarding its mechanism of action, molecular target(s), or modality. No clinical trial results or regulatory approvals have been reported for this compound[1][4].

Beyond the preview

Go deeper on DM-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DM-007.

Explore the full profile